Elias Karam: ACCENT pooled analysis published in JCO

Elias Karam, Hematology and Medical Oncology Fellow at Gustave Roussy, shared a post on LinkedIn about a recent paper by Benoist Chibaudel et al., titled “Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis” published on Journal of Clinic Oncology.

Auhtors: Benoist Chibaudel, Morteza Raeisi, Romain Cohen, Greg Yothers, Richard M. Goldberg, Jean-Baptiste Bachet, Norman Wolmark, Takayuki Yoshino, Hans-Joachim Schmoll, Rachel Kerr, Sara Lonardi, Thomas J. George, Einat Shacham-Shmueli, Qian Shi, Thierry André, Aimery de Gramont.

“ACCENT pooled analysis published in JCO:
No benefit of OX was observed for OS in either the low-risk or even in high-risk patient subgroup, stage II colon cancer
OX should not be anymore our standard of care even in high risk stage II colon cancer population.
FP (CAPE or 5-FU) does the job.”

Source: Elias Karam/LinkedIn